Chemistry and Pharmacology of Anticancer Drugs, Second Edition, Thurston

Автор: Carmen Avendano
Название: Medicinal Chemistry of Anticancer Drugs
ISBN: 0444626492 ISBN-13(EAN): 9780444626493
Издательство: Elsevier Science
Рейтинг:
Цена: 23244.00 р.
Наличие на складе: Поставка под заказ.

Описание: Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. . Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells, and resistance to antitumor drugs continues to be investigated. While these therapies are in their infancy, they hold promise of more effective therapies with fewer side effects. . Although many books are available that deal with clinical aspects of cancer chemotherapy, this book provides a sorely needed update from the point of view of medicinal chemistry and drug design.

Автор: Muriel, Le Roux
Название: Anticancer Drugs: Navelbine(R) and Taxotere(R)
ISBN: 1785481452 ISBN-13(EAN): 9781785481451
Издательство: Elsevier Science
Рейтинг:
Цена: 16001.00 р.
Наличие на складе: Есть у поставщика Поставка под заказ.

Описание: Among the many forms of cancer treatment, chemotherapy remains an important part of the arsenal in which Navelbine and Taxotere play a major role.These medicines result from molecules discovered by French researchers of the Institut de Chimie des Substances Naturelles (ICSN) of the CNRS, directed by Pierre Potier. By recounting this history, the authors of this book attempt to illustrate how the work of themselves and others, united in a community, has helped obtain these results. After having explained the strategy of the French policy makers to promote the French chemistry of natural substances, the authors explore how the academic efforts in this field have evolved, and the alignment between science and its applications has become increasingly present. The contributions of the CNRS to the industry, and vice versa, offer an alternative image of public research relationships and industrial research, where CNRS researchers are able to extend the limits of freedom and creativity. It is to account for this complexity that the authors here have chosen to write this history together, which is in a sense exemplary.Due to an association between history and chemistry, this book explains these discoveries by placing them in their specific politic, economic and scientific contexts.

Автор: L. Harivardhan Reddy; Patrick Couvreur
Название: Macromolecular Anticancer Therapeutics
ISBN: 1461424925 ISBN-13(EAN): 9781461424925
Издательство: Springer
Рейтинг:
Цена: 36570.00 р.
Наличие на складе: Есть у поставщика Поставка под заказ.

Описание: This book details the macromolecular therapeutics for cancer therapy. It also covers the classification of these anticancer drugs based on therapeutic targets and elaborates on different classes of anticancer therapeutics.

Автор: Teicher
Название: Anticancer Drug Development Guide. 2ed.2004
ISBN: 1588292282 ISBN-13(EAN): 9781588292285
Издательство: Springer
Рейтинг:
Цена: 34799.00 р.
Наличие на складе: Есть у поставщика Поставка под заказ.

Описание: This thoroughly updated and expanded second edition of Beverly Teicher's widely used classic survey provides a step-by-step guide to anticancer drug development from initial design through FDA approval. The authors have included new material on the use of high throughput screening in industry, on specialized in vitro/in vivo procedures employed by the National Cancer Institute (NCI) in preclinical drug evaluations, and on nonclinical testing to support both human clinical trials, as well as trials of biologic oncology products. The chapters on phase I, II, and III clinical trials and on novel phase II clinical trial designs for targeted therapies have been significantly updated, along with those on cancer drug development in Europe, working with the NCI, and the FDA's role in cancer drug development and setting requirements for approval.